Honasa had announced the acquisition on June 23, subject to the completion of conditions precedent.
Also read: Sai Parenterals’ Australian OTC supply book hits ₹1,506 crore with second contract renewal
FMCG firm to continue nutraceutical strategy
Honasa said it will continue to evaluate organic and inorganic opportunities in the nutraceuticals category.The development comes after the company reported a 118.4% year-on-year increase in net profit to ₹90.2 crore for Q1FY27, compared with ₹41.3 crore in the year-ago quarter. Revenue rose 27% to a record ₹756 crore from ₹595.2 crore, while EBITDA increased to ₹110.1 crore from ₹45.7 crore.
The company’s EBITDA margin improved to 14.57% from 7.68% a year earlier, while its profit after tax margin stood at 11.5%.
Also read: Reserve Bank of India net absorbed $561 million in June as inflows picked up
Honasa share price performance
Shares of Honasa Consumer ended at ₹485 on August 13, down 1.18%. The stock has gained 69.61% so far this year and 62.21% over the past year. It has risen 59.47% in six months, 24.09% in three months and 8.23% over one month. The stock is up 2.30% over the past week and 3.61% over two years.
(Edited by : Ajay Vaishnav)
